Venture-backed medtechs rush for the exit

Venture investors in medical device companies seem to have the Midas touch. VCs active in the healthcare space have been able to raise huge funds with relative ease in recent years, and in 2020 ploughed $6.4bn into private diagnostics and device makers.

And they are seeing returns faster than they have for some time. A new Evaluate Vantage analysis finds that last year the median time to buyout or IPO for venture-backed medtechs dropped to below a decade. The precipitous drop in the wait for an acquisition is particularly eye-catching, and hopefully a sign of buyers’ faith in early-stage innovators.